High-grade B-cell lymphoma

Abstract

Introduction. Aggressive B-cell lymphomas are a heterogeneous group of diseases with various clinical, patohistological, genetic characteristics and a variety of treatment outcomes. Diffuse large B-cell lymphoma is the most common lymphoma in European countries, some lymphomas are recognized as specifically aggressive, providing non-adequate response to the standard treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). High-grade B-lymphomas. One group consists of those which are carriers of the c-myc, bcl-2 or bcl-6 rearrangement established by Fluorescence in situ hybridization, and are called high grade B lymphomas, which can be double hit or triple hit. The other group consists of those with blastoid morphology, which are not carriers of the c-myc, bcl-2 and bcl- 6 rearrangement and are called Not Otherwise Specified. This heterogeneous group is a carrier of a single myc mutation in 45% of cases, in 15% of patients, an additional analysis of gene expression profiling indicates the presence of high grade B lymphomas double hit sig+. Extranodal localization with Central Nervous System involvement is frequently reported. Clinical staging and disease progression along with risk assessment by means of IPI scores and aaIPI scores in patients with high-grade B-lymphomas. Diagnostic procedures during the clinical interview, physical examination, laboratory analyses and various additional diagnostic procedures. High-grade Blymphomas treatment. Studies indicate more intensive induction chemotherapy including central nervous system prophylaxis for these patients. Conclusion. The question of how to choose the most effective therapeutic strategy in high grade B lymphomas is still open at this moment, and examinations are focused on the research of molecular mechanisms of lymphomagenesis.